Kenneth C. Hohmeier, Grace Broussard, Melissa Tyszko, Kelly Barland, Kristi Carlston, Yingjia Wei, Craig Field, Adam J. Gordon, Alina Cernasev, Gerald Cochran
{"title":"社区药剂师对减少阿片类药物和酒精共同使用的影响:一项药物治疗管理干预的随机对照试验","authors":"Kenneth C. Hohmeier, Grace Broussard, Melissa Tyszko, Kelly Barland, Kristi Carlston, Yingjia Wei, Craig Field, Adam J. Gordon, Alina Cernasev, Gerald Cochran","doi":"10.1002/jac5.70113","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high-risk drinking. We adapted a medication therapy management-based intervention to address co-use and tested its feasibility, acceptability, and preliminary efficacy.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>This pilot study enrolled adult, English-speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol-targeted brief intervention-medication therapy management (ABI-MTM). ABI-MTM included two pharmacist-delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co-use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (> high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI-MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI-MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI-MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>ABI-MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.</p>\n </section>\n </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 10","pages":"991-1002"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Community Pharmacists on Reducing Opioid and Alcohol Co-Use: A Pilot Randomized Control Trial of a Medication Therapy Management Intervention\",\"authors\":\"Kenneth C. Hohmeier, Grace Broussard, Melissa Tyszko, Kelly Barland, Kristi Carlston, Yingjia Wei, Craig Field, Adam J. Gordon, Alina Cernasev, Gerald Cochran\",\"doi\":\"10.1002/jac5.70113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high-risk drinking. We adapted a medication therapy management-based intervention to address co-use and tested its feasibility, acceptability, and preliminary efficacy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>This pilot study enrolled adult, English-speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol-targeted brief intervention-medication therapy management (ABI-MTM). ABI-MTM included two pharmacist-delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co-use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (> high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI-MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI-MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI-MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>ABI-MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.</p>\\n </section>\\n </div>\",\"PeriodicalId\":73966,\"journal\":{\"name\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"volume\":\"8 10\",\"pages\":\"991-1002\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70113\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Impact of Community Pharmacists on Reducing Opioid and Alcohol Co-Use: A Pilot Randomized Control Trial of a Medication Therapy Management Intervention
Background
Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high-risk drinking. We adapted a medication therapy management-based intervention to address co-use and tested its feasibility, acceptability, and preliminary efficacy.
Design
This pilot study enrolled adult, English-speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol-targeted brief intervention-medication therapy management (ABI-MTM). ABI-MTM included two pharmacist-delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co-use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.
Results
We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (> high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI-MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI-MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI-MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.
Conclusion
ABI-MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.